80230 Drug assay infliximab
Also known as: infliximab level, Remicade level
Laboratory quantitative drug assay for infliximab to assess serum level and antibodies for therapeutic drug monitoring in inflammatory disease treatment.
In Plain Language
infliximab blood test; biological medication level
Clinical Context
Monitors tumor necrosis factor-alpha inhibitor levels and anti-drug antibodies in inflammatory bowel disease and rheumatoid arthritis for optimal therapeutic response.
RVU Information
CPT 80230 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Lab and pathology codes require an order from the treating provider with clinical indication. For molecular pathology and genetic testing, document the specific analytes tested and clinical rationale.
How This Code Compares
This code has a work RVU of 0.00, meaning it does not have a physician work component assigned by CMS. In the Pathology & Lab category, 94% of codes share this characteristic.
Specialties
Frequently Asked Questions
What is CPT code 80230?
CPT 80230 (Drug assay infliximab) is a Pathology & Lab code. Laboratory quantitative drug assay for infliximab to assess serum level and antibodies for therapeutic drug monitoring in inflammatory disease treatment.
Who uses CPT code 80230?
CPT 80230 is used by Pathology, Gastroenterology, Rheumatology. Monitors tumor necrosis factor-alpha inhibitor levels and anti-drug antibodies in inflammatory bowel disease and rheumatoid arthritis for optimal therapeutic response.
When is CPT 80230 used?
Monitors tumor necrosis factor-alpha inhibitor levels and anti-drug antibodies in inflammatory bowel disease and rheumatoid arthritis for optimal therapeutic response.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.